CEO, Pinteon Therapeutics
Martin Jefson, Ph.D., received his degree in Chemistry from Cornell University, and began his career at Pfizer Central Research in 1982, where he spent 27 years, ultimately becoming head of CNS Research. Between 1994 and 2009, teams led or managed by Dr. Jefson discovered more than 40 development candidates, including many prototype molecules with novel mechanisms of action. One of these candidates, the nicotinic receptor partial agonist varenicline (Chantix™), is approved worldwide as an aid to smoking cessation. Since leaving Pfizer in 2009, he has worked as a pharmaceutical research consultant, supporting the efforts of several venture capital partnerships and more than 20 biotechnology and pharmaceutical companies. Dr. Jefson was the founding CSO of two Atlas Ventures portfolio companies, Rodin and Ataxion (now Cadent), focused on the discovery and development of novel therapeutics for neurological disorders. He served in those roles through March 2016. Dr. Jefson is currently the CEO of Pinteon Therapeutics, a Morningside Venture backed company focused on the treatment of neurological disorders such as AD, TBI and CTE.